Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 53,825

Document Document Title
WO/2024/011116A2
The disclosure relates to compounds that act as irreversible inhibitors interleukin 1 (IL-1 ) receptor-associated kinases (IRAKs); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediate...  
WO/2024/007985A1
The present application provides a compound represented by formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same. The compound, the stereoisomer of the compoun...  
WO/2024/009215A1
Provided herein are novel compounds, e.g., those of Formula (I), as GCN2 inhibitors. Also provided are pharmaceutical compositions including one or more of the novel compounds, and pharmaceutical uses thereof. Compounds provided herein c...  
WO/2024/008113A1
The present invention relates to a formamide-substituted heterotricyclic derivative represented by formula (I), a method for preparing same, and use thereof. The present invention further relates to a pharmaceutical composition comprisin...  
WO/2024/008179A1
Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D.  
WO/2024/008138A1
A pharmaceutical combination of a 1,3,5-triazine derivative. Specifically, the present invention relates to a pharmaceutical combination of a compound of formula I, a tautomer thereof or a pharmaceutically acceptable salt thereof, and az...  
WO/2024/010015A1
Compounds represented by general formula (1), the compounds having strong inhibitory action against mPGES-1 and being useful as active ingredients for pharmaceuticals for the treatment of inflammation and the like.  
WO/2024/008941A1
Compounds of Formula (I): wherein R1, R2, R3, R4 and are as defined in the description. Medicaments.  
WO/2024/008121A1
Disclosed are a series of difluoro-substituted azabicyclo compounds and uses thereof, and specifically disclosed are a compound represented by formula (V) and a pharmaceutically acceptable salt thereof.  
WO/2024/008833A1
A prodrug kit for multifactorial dynamic chemotherapy comprises N different small-molecule- drug-conjugates selected from the group comprising Si = Fci―Li―Cti with i = 1, 2, 3, …., 360 wherein 2 ≤ N ≤ 360, Fci is a moiety that ...  
WO/2023/169480A9
Provided are a deuterated compound represented by formula IA or a pharmaceutically acceptable salt thereof, a preparation method therefor and a use thereof. Some deuterated compounds have a half-life period of up to 2-4 times that of BVD...  
WO/2024/008083A1
A compound as a CDK7 kinase inhibitor and the use thereof. The compound has a structure as shown in formula I, can be used as a cyclin-dependent kinase 7 (CDK7) inhibitor, and is used for treating or preventing proliferative diseases (su...  
WO/2024/011075A2
A light delivery device for delivering light therapy includes a light source configured to emit light, one or more first piercing members extending from a distal surface of the light delivery device, the one or more first piercing member...  
WO/2024/008048A1
Disclosed is a novel substituted pyrimidoheterocyclic compound, which can be used as an EGFR mutation target inhibitor. Specifically disclosed are a compound represented by the structure in formula (I) or pharmaceutically acceptable salt...  
WO/2024/009144A1
Provided herein is a method for the manufacture of a compound of obicetrapib and salts thereof, such as calcium salts thereof. Also provided herein is amorphous obicetrapib hemicalcium. New intermediates for use in the synthesis of obice...  
WO/2024/010818A2
This disclosure is directed to proteolysis targeting chimera (PROTAC) of selective androgen receptor degrader (SARD) compounds which are useful in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, ...  
WO/2024/010585A1
Provided herein are compounds of formula (I) or (I-A), which act as non-covalent inhibitors of SARS-CoV2 main protease (Mpro). The compounds of formula (I) or (I-A) are useful in treating, ameliorating, and/or preventing COVID-19 infecti...  
WO/2024/010817A2
This disclosure is directed to selective androgen receptor degrader (SARD) compounds, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple ne...  
WO/2024/009308A1
The present invention involves novel TRPV2 blockers, pharmaceutical compositions comprising the same and uses thereof for the treatment of inflammatory response in inflammation mediated disease processes.  
WO/2024/002206A1
Provided is a bifunctional compound, or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein the bifunctional compound is represented by Formula (I) : ABM-L-CLM (I); wherein: ABM is an androgen rec...  
WO/2024/006559A1
Compounds are provided for inhibiting NLRP3 inflammasome generally, or for treating a NLRP3 inflammasome dependent condition more specifically, by contacting the NLRP3 inflammasome or administering to a subject in need thereof, respectiv...  
WO/2024/000615A1
A compound capable of being used as a protein tyrosine kinase inhibitor, which can inhibit AXL, KDR and/or CSF-1R kinase. The compound can also be used for preparing a drug for treating a tumor and a related disease caused by AXL, KDR an...  
WO/2024/002328A1
Provided are a nitrogen-containing compound and use thereof. Specifically, provided is a nitrogen-containing compound represented by formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, a met...  
WO/2024/002377A1
Provided is a class of compounds with methyltransferase inhibitory activity. Specifically, provided is a class of compounds with PRMT5 inhibitory activity. The compounds can be used for preparing a pharmaceutical composition for treating...  
WO/2024/003749A1
Provided are novel compounds represented by Formula (I) which degrade CK1α (casein kinase 1 alpha), and methods of degrading CK1α, or preventing or treating blood cancer by administering the compounds to a subject in need thereof.  
WO/2024/006776A1
The application relates to bifunctional compounds which act as degraders of the estrogen receptor alpha (ERα) and are useful for treating disorders associated with ERα-mediated transcription regulation such as endometriosis and cancer....  
WO/2024/006956A2
The disclosure relates to compounds that act as inhibitors of VCPIP1 and related DUBs; pharmaceutical compositions comprising the compounds; and methods of treating or preventing DUB-mediated disorders, including cancer and other prolife...  
WO/2024/005118A1
The purpose of the present invention is to provide an organic electroluminescent element which achieves excellent drive voltage characteristics and excellent current efficiency characteristics at the same time, while having a small chang...  
WO/2024/003535A2
Disclosed are compounds of the formula (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt or N-oxide thereof: (I) wherein R1, R2, R3, R4, R5, n, m, and x are as defined herein. Compounds of the invention may be suit...  
WO/2024/000877A1
The present invention belongs to the technical field of organic synthesis, and particularly relates to a preparation method for nicotine. The preparation method for nicotine comprises the following steps: photocatalytically synthesizing ...  
WO/2024/006929A1
There is provided a compound of Formula (I): or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of wherein the various substituents are defined herein,  
WO/2024/006985A1
Described herein are fatty acid amide hydrolase (FAAH) cleavable prodrugs of compounds that modulate sphingosine- 1 -phosphate receptor 5 (S1P5), methods of making such compounds, pharmaceutical compositions and medicaments comprising su...  
WO/2024/006403A2
The present disclosure relates to compounds, compositions, and methods for treating diseases or conditions mediated by aberrant histone deacetylase 8 (HDAC8) activity.  
WO/2024/006881A1
Provided herein are compounds and compositions thereof that reduce WEE1 kinase protein levels. In some embodiments, the compounds and compositions are provided for treatment WEE1 associated diseases such as cancer.  
WO/2024/006781A1
The application relates to bifunctional compounds of the general formula I-3' which act as degraders of the estrogen receptor alpha(ERα) and are useful for treating disorders associated with ERα-mediated transcription regulation such a...  
WO/2024/003915A1
A crystalline form of indaziflam, processes for the preparation thereof, an agrochemical composition containing the crystalline form of indaziflam and a process for the preparation of the agrochemical composition.  
WO/2024/002853A1
A precursor compound and radiotracer for targeting fibroblast activation protein comprise a chelator Ch and ligand TV with Ch = (Formula) with R = | ‒CH3 or |‒CH2COOH; and TV = (Formula).  
WO/2024/000401A1
The present invention relates to compounds of formula (I) preferred compounds are e.g. 2-((l-(4-oxo-3,4-dihydroquinazolin-8-yl)ethyl)amino)benzoic acid derivatives of formula (ll-A) an exemplary compound is e.g. 2-((l-(2-(isoindolin-2-yl...  
WO/2024/000763A1
Provided are a G9a/GLP covalent inhibitor and a preparation method therefor and a use thereof. The G9a/GLP covalent inhibitor is a compound having a structure as shown in formula (I) and a salt thereof:  
WO/2024/003259A1
The present invention covers heterocyclic compounds of general formula (I): Formula (I), wherein (I'), Formula (I') represents a heterocyclic ring, said compound of general formula (I) being selected from the group consisting of: Formula...  
WO/2024/005578A1
The present invention relates to novel indenone derivatives, isomers thereof or pharmaceutically acceptable salts thereof, and uses thereof. The indenone derivatives according to the present invention may be advantageously used for (i) t...  
WO/2024/005032A1
In the production of crops in agriculture, horticulture, etc., due to factors such as damages caused by harmful bugs and the like still being significant and the emergence of harmful bugs resistant to existing drugs, there has been a dem...  
WO/2024/002379A1
Provided are a compound used as a WDR5 inhibitor or a pharmaceutically acceptable salt thereof, and a use of the compound in preparation of a drug. The compound has high affinity to WDR5, and compared with the prior art, has higher inhib...  
WO/2024/005486A1
The present specification relates to a compound of chemical formula 1 and an organic light-emitting element comprising same.  
WO/2024/002353A1
Provided are a pharmaceutically acceptable salt and a crystal form of a nitrogen-containing bridge heterocyclic derivative, and a method for preparing same. Specifically provided are different salt forms and crystal forms of salts of 4-(...  
WO/2024/002223A1
The present invention relates to a heterocyclic derivative as an inhibitor, a method for preparing same, and use thereof. In particular, the present invention relates to a compound represented by general formula (I), a method for prepari...  
WO/2024/006982A1
The present disclosure provides compounds and salts thereof, and compositions, which are useful in the prevention and/or treatment of HIV.  
WO/2024/006897A1
Disclosed herein are compounds and methods of treating diseases and/or conditions associated with FGFR inhibition.  
WO/2023/250029A1
The present disclosure provides certain bifunctional compounds containing substituted pyrimidine derivatives substituted at the 4-position with a cyclic group that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin prote...  
WO/2023/246873A1
Disclosed in the present application are a series of amino-substituted heteroaryl derivatives and a use thereof. In particular, disclosed are a compound represented by formula (P) and a pharmaceutically acceptable salt thereof.  

Matches 251 - 300 out of 53,825